Tectonic Therapeutics TECX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $20.87M+27.7% | $16.34M-3.5% | $16.93M-1.5% | $17.19M+31.8% | $13.04M+42.4% | ||
| $6.43M+24.3% | $5.18M+4.3% | $4.96M-3.6% | $5.15M-2.2% | $5.26M+8.8% | ||
| $27.3M+26.9% | $21.52M-1.7% | $21.89M-2.0% | $22.33M+22.0% | $18.3M+30.8% | ||
| $27.3M+26.9% | $21.52M-1.7% | $21.89M-2.0% | $22.33M+22.0% | $18.3M+30.8% | ||
| -$27.3M-26.9% | -$21.52M+1.7% | -$21.89M+2.0% | -$22.33M-22.0% | -$18.3M-30.8% | ||
| $8K-33.3% | $12K-14.3% | $14K-17.6% | $17K-15.0% | $20K-9.1% | ||
| $2.18M-14.9% | $2.56M-11.6% | $2.9M-14.4% | $3.39M+38.7% | $2.44M+40.9% | ||
| $2.06M-19.0% | $2.54M-10.9% | $2.86M-14.1% | $3.32M+39.0% | $2.39M+47.8% | ||
| —— | -$18.97M+0.3% | -$19.04M-0.1% | -$19.01M-19.5% | -$15.91M-28.6% | ||
| $25.2M+9,823% | $254K— | $0-100% | $976K-93.9% | $15.91M— | ||
| -$25.24M-31.3% | -$19.23M-1.0% | -$19.04M+4.7% | -$19.98M-25.6% | -$15.91M-28.6% | ||
| -$1.34-30.1% | -$1.03-1.0% | -$1.02+4.7% | -$1.07-15.1% | -$0.93— | ||
| -$1.34-30.1% | -$1.03-1.0% | -$1.02+4.7% | -$1.07-15.1% | -$0.93— | ||
| 18.8M+2.4% | 18.3M-2.1% | 18.7M+0.2% | 18.7M+8.9% | 17.2M+102% | ||
| 18.8M+2.4% | 18.3M-2.1% | 18.7M+0.2% | 18.7M+8.9% | 17.2M+102% | ||
| $37K+276% | -$21K+19.2% | -$26K+49.0% | -$51K-629% | -$7K-109% | ||
| $25.2M+31.0% | $19.25M+1.0% | $19.06M-4.9% | $20.04M+25.9% | $15.91M+29.4% | ||
| -$113K-1,313% | -$8K+74.2% | -$31K+35.4% | -$48K-50.0% | -$32K+66.3% | ||
| -$27.3M-26.9% | -$21.52M+1.7% | -$21.89M+2.0% | -$22.33M-22.0% | -$18.3M-30.8% | ||
| -$27M-27.4% | -$21.18M+1.7% | -$21.55M+2.0% | -$21.99M-22.6% | -$17.94M-33.0% | ||
| -$27M-27.4% | -$21.18M+1.7% | -$21.55M+2.0% | -$21.99M-22.6% | -$17.94M-33.0% | ||
| -$27.3M-26.9% | -$21.52M+1.7% | -$21.89M+2.0% | -$22.33M-22.0% | -$18.3M-30.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Tectonic Therapeutics profitable?
- Tectonic Therapeutics is not currently profitable: it reported a net loss of $83.5M over the trailing twelve months.
- What is Tectonic Therapeutics's earnings per share?
- Tectonic Therapeutics's diluted EPS over the trailing twelve months is $-4.46.
- Where does Tectonic Therapeutics's income statement data come from?
- Every line is extracted from Tectonic Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.